Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020
Basel, 19 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it presented the latest results from three Phase III studies from the Tecentriq ® (atezolizumab) clinical development programme in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.“While we have made great progress in the treatment of many forms of breast cancer, TNBC remains an aggressive and difficult-to-treat disease,” said Levi Garraway, M.D., Ph.D., Roche's Chief Medical Officer and Head of Global Product Development. “We are proud of our work to address...
Source: Roche Investor Update - September 19, 2020 Category: Pharmaceuticals Source Type: news

Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020
Basel, 19 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it presented the latest results from three Phase III studies from the Tecentriq ® (atezolizumab) clinical development programme in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.“While we have made great progress in the treatment of many forms of breast cancer, TNBC remains an aggressive and difficult-to-treat disease,” said Levi Garraway, M.D., Ph.D., Roche's Chief Medical Officer and Head of Global Product Development. “We are proud of our work to address...
Source: Roche Media News - September 19, 2020 Category: Pharmaceuticals Source Type: news

Ruth Bader Ginsburg Dies from Pancreatic Cancer
The three-time cancer survivor faced her most recent troubles in late 2018, when she had surgery for lung cancer that was discovered after she broke several ribs in a fall in her chambers. In January of 2020, Ginsburg announced that she was cancer free. But in July she said she was undergoing chemotherapy after a lesion was found on her liver. (Source: WebMD Health)
Source: WebMD Health - September 19, 2020 Category: Consumer Health News Source Type: news

How Cancer Shaped Justice Ruth Bader Ginsburg ’s Life and Work
The name Ruth Bader Ginsburg became almost synonymous with strength and stamina as she rose to prominence in judicial and feminist circles throughout her long career. Famously nicknamed the Notorious RBG and known for her grueling fitness regimen, the late Supreme Court justice also struggled with cancer and other health issues for the better part of her time on the bench — culminating with her death on Sept. 18 at the age of 87 of complications from metastatic pancreatic cancer. Ginsburg’s health issues became public in 1999, six years after her appointment to the Supreme Court, when she had surgery for early-...
Source: TIME: Health - September 19, 2020 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Cancer healthytime remembrance Source Type: news

Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expe...
Source: Roche Investor Update - September 18, 2020 Category: Pharmaceuticals Source Type: news

Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expe...
Source: Roche Media News - September 18, 2020 Category: Pharmaceuticals Source Type: news

Mother and Son Draw Hope, Healing From Shared Cancer Treatment
THURSDAY, Sept. 17, 2020 -- Families bond over lots of shared experiences -- but one Leslie Seigel and her adult son, Josh, never expected to share was battling cancer. Soon after Leslie finished chemotherapy for an aggressive form of breast... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 17, 2020 Category: General Medicine Source Type: news

Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
Basel, 17 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results include data from three phase III studies across the Tecentriq® (atezolizumab) triple-negative breast cancer (TNBC) programme. Central nervous system (CNS) efficacy data from integrated analyses of the pivotal phase II Rozlytrek® STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented in addition to re...
Source: Roche Investor Update - September 17, 2020 Category: Pharmaceuticals Source Type: news

Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
Basel, 17 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results include data from three phase III studies across the Tecentriq® (atezolizumab) triple-negative breast cancer (TNBC) programme. Central nervous system (CNS) efficacy data from integrated analyses of the pivotal phase II Rozlytrek® STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented in addition to re...
Source: Roche Media News - September 17, 2020 Category: Pharmaceuticals Source Type: news

Pattern of gut bacteria linked to effectiveness of chemotherapy in breast cancer patients
(European Organisation for Research and Treatment of Cancer) Researchers studying the activity of gut bacteria in breast cancer patients have found a possible link with how well their chemotherapy works. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 17, 2020 Category: Cancer & Oncology Source Type: news

Kang finds keys to control the 'driver of cancer's aggressiveness'
(Princeton University) A dangerous protein named SNAI2 helps cancers metastasize and shields cancer from both the immune system and chemotherapy. Worse, SNAI2 is in a family of proteins that are notoriously hard to fight with drugs. But now Princeton University's Yibin Kang and his colleagues have found a way to use the cell's recycling system to control SNAI2, providing a new possibility for treatments. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 17, 2020 Category: Cancer & Oncology Source Type: news

CU researchers now better understand ovarian cancer tumors and treatment outcomes
(University of Colorado Anschutz Medical Campus) After nearly four years of work, a group of researchers and clinicians from CU published a paper this week in the Clinical Cancer Research that shares findings from research looking at how the composition of ovarian cancer tumors changes during chemotherapy and contributes to therapeutic response. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 15, 2020 Category: Cancer & Oncology Source Type: news

Cigarette smoking associated with worse outcomes for bladder cancer patients after surgery
(University of Southern California - Health Sciences) Study from Keck Medicine of USC links smoking with a higher risk of death and cancer recurrence, and less responsiveness to chemotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 15, 2020 Category: Cancer & Oncology Source Type: news

Mesothelioma Trial to Test Cancer Vaccine with Immunotherapy
A research team at Oslo University Hospital in Norway has opened a mesothelioma clinical trial using the novel UV1 cancer vaccine alongside a promising immunotherapy combination. UV1 is a peptide-based vaccine designed to induce a specific T-cell response and increase the effectiveness of the immunotherapy drugs. This is the first time UV1 will be studied with mesothelioma cancer, but it already has shown safety and signs of efficacy when used on malignant melanoma, prostate cancer and lung cancer in studies worldwide. It will be used with the immunotherapy combination of nivolumab and ipilimumab, also known by brand names...
Source: Asbestos and Mesothelioma News - September 14, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

First US Trial to Test Aerosolized Chemo in Advanced Cancers First US Trial to Test Aerosolized Chemo in Advanced Cancers
A team of US researchers is investigating whether pressurized intraperitoneal aerosolized chemotherapy (PIPAC) can benefit patients with advanced cancer and peritoneal carcinomatosis.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 10, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Few High-Grade Soft Tissue Sarcoma Patients Receive Chemo
THURSDAY, Sept. 10, 2020 -- The rates of adults with high-grade soft tissue sarcoma (STS) who receive chemotherapy may be lower than expected, indicating a need for more aggressive systemic treatments, according to a study published in the August... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 10, 2020 Category: Pharmaceuticals Source Type: news

The web of death
(Max Planck Institute for Polymer Research) Cancer is one of the most frequent causes of death. Chemotherapy is often used as a treatment, but also brings side effects for healthy organs. Scientists around David Ng, group leader at the Max Planck Institute for Polymer Research, are now trying to take a completely different approach: By means of targeted and localized disruption of the cancer cells' structure, its self-destruction mechanism can be activated. In laboratory experiments, they have already demonstrated initial successes. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 10, 2020 Category: Biology Source Type: news

09.09.20: Not intended for U.S. and UK Media
New England Journal of Medicine publishes final overall survival data for Nubeqa™ (darolutamide) showing treatment significantly extends life in men with non-metastatic prostate cancerMen with non-metastatic castration-resistant prostate cancer (nmCRPC) receiving darolutamide plus androgen deprivation therapy (ADT) had a significant improvement in overall survival (OS) compared to placebo plus ADT (HR=0.69, 95% CI 0.53-0.88; p=0.003) / Darolutamide significantly improved all other secondary endpoints, including time to first initiation of cytotoxic chemotherapy and first symptomatic skeletal event (SSE) / The safety ...
Source: Bayer IR Newsfeed: Events - September 10, 2020 Category: Pharmaceuticals Source Type: news

Advanced Care at Home means leaving the hospital sooner
For John Jolly, retirement means enjoying time with his wife, gardening and walking 10,000 steps daily. But after chemotherapy to treat bladder cancer in 2018, John has had recurrent kidney issues that sometime require hospitalization. The new Advanced Care at Home program, which is part of the Mayo Clinic Platform, got the 72-year-old former certified [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 10, 2020 Category: Databases & Libraries Source Type: news

New England Journal of Medicine publishes final overall survival data for Nubeqa ™ (darolutamide) showing treatment significantly extends life in men with non-metastatic prostate cancer (for specialized target groups only)
Men with non-metastatic castration-resistant prostate cancer (nmCRPC) receiving darolutamide plus androgen deprivation therapy (ADT) had a significant improvement in overall survival (OS) compared to placebo plus ADT (HR=0.69, 95% CI 0.53-0.88; p=0.003) / Darolutamide significantly improved all other secondary endpoints, including time to first initiation of cytotoxic chemotherapy and first symptomatic skeletal event (SSE) / The safety profile at final analysis remains consistent with the earlier analysis; overall, the rate of adverse events was comparable to ADT alone (Source: Bayer Company News)
Source: Bayer Company News - September 9, 2020 Category: Pharmaceuticals Source Type: news

Study finds botanical effective for chemo-resistant colon cancer
(City of Hope) The natural botanical Andrographis paniculata, when given in conjunction with chemotherapy, may eventually change the way doctors treat chemotherapy-resistant colorectal cancer. Published in the journal Carcinogenesis, the study's goal was to use a natural substance that, given as an adjunct treatment along with chemotherapy, would not only be nontoxic but would succeed in killing chemo-resistant cancer cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 9, 2020 Category: Cancer & Oncology Source Type: news

A risk-stratified approach to planned cancer care during the COVID-19 pandemic: the Royal Marsden experience, NICE
This example details a multi-disciplinary risk stratified approach by the Royal Marsden to minimising the risks associated with COVID-19 for planned cancer care (diagnostics, surgery, chemotherapy and clinical trials). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - September 8, 2020 Category: Consumer Health News Source Type: news

Chemotherapy drug more effective when combined with microbubbles
(American Institute of Physics) Hepatocellular carcinoma is usually treated by blocking the flow of blood to the tumor to induce cancer cell death, but the common treatment, transarterial chemoembolization, is invasive and too imprecise to be a local drug delivery method. Aiming to increase the precision, researchers at Tulane University created a treatment that involves vaporizing tiny droplets of perfluorocarbon, a common organic material composed of carbon and fluorine. The method of gas embolization is published in APL Bioengineering. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 8, 2020 Category: International Medicine & Public Health Source Type: news

Roche announces FDA approval of Gavreto (pralsetinib) for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer
             Basel, 7 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States (US) Food and Drug Administration (FDA) has approved Gavreto ™ (pralsetinib) for the treatment of adults with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. This indication was approved under the FDA’s Accelerated Approval programme, based on data from the phase I/II ARROW study. Continued approval for this indication may be contingent upon verifica...
Source: Roche Media News - September 7, 2020 Category: Pharmaceuticals Source Type: news

Roche announces FDA approval of Gavreto (pralsetinib) for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer
             Basel, 7 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States (US) Food and Drug Administration (FDA) has approved Gavreto ™ (pralsetinib) for the treatment of adults with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. This indication was approved under the FDA’s Accelerated Approval programme, based on data from the phase I/II ARROW study. Continued approval for this indication may be contingent upon verifica...
Source: Roche Investor Update - September 7, 2020 Category: Pharmaceuticals Source Type: news

Mayo Clinic Q and A: Lung cancer care during the COVID-19 pandemic
DEAR MAYO CLINIC: My father has been a heavy smoker for most of his life. He was diagnosed with lung cancer recently. He underwent surgery and several chemotherapy treatments prior to the outbreak of COVID-19. He is getting a bit agitated being home, and we are wondering if it is safe for him to venture out [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 6, 2020 Category: Databases & Libraries Source Type: news

New vacuum-powered biopsy could spare thousands of women from major breast cancer surgery
RACHEL ELLIS: Using 'vacuum' technology to help pinpoint the location of breast cancer left after chemotherapy could spare thousands of women major surgery. (Source: the Mail online | Health)
Source: the Mail online | Health - September 1, 2020 Category: Consumer Health News Source Type: news

Hematologic Cancers Tied to More Severe COVID-19 Illness Hematologic Cancers Tied to More Severe COVID-19 Illness
Cancer type, age, gender, and use of chemotherapy all increased the risk of severe COVID-19 infection and/or related mortality.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 31, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Genomic analysis predicts survival benefit of adjuvant chemotherapy following radiotherapy over radiotherapy alone in low-grade gliomas in NRG Oncology clinical trial
(NRG Oncology) A practice-changing study, NRG Oncology clinical trial NRG-RTOG 9802, has demonstrated, for the first time, a survival benefit of adjuvant chemotherapy following radiotherapy over radiotherapy alone in certain subgroups of patients with high-risk, low-grade glioma (WHO classification: LGG, grade II), a type of brain tumor that originates from glial cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 31, 2020 Category: Cancer & Oncology Source Type: news

Recent Chemotherapy Not Tied to Worse COVID-19 Outcomes Recent Chemotherapy Not Tied to Worse COVID-19 Outcomes
Certain malignancies and their consequences are associated with higher rates of severe or critical COVID-19 illness, but recent cytotoxic chemotherapy is not, according to new research.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - August 28, 2020 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Oncologists Were Paid To Prescribe Generic Chemotherapy (Here ’s Why It Didn’t Change A Thing)
Incentivizing physicians to prescribe expensive brand-name chemotherapies instead of generic ones risks burdening patients with high out-of-pocket costs. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - August 27, 2020 Category: Pharmaceuticals Authors: Peter Ubel, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma Source Type: news

New therapy targets breast cancer metastases in brain
(Northwestern University) When breast cancer spreads to the brain, the prognosis is grim. Patients only have about six months to live. Women with HER2-positive breast cancer tend to develop brain metastases in up to 55% of cases. Chemotherapy drugs targeting breast cancer cells in the brain aren't effective, because they can't cross the blood-brain-barrier. But a new combination therapy targeting breast cancer tumors in the brain dramatically decreased tumor size and increased survival in a preclinical study. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 26, 2020 Category: Cancer & Oncology Source Type: news

Immune protein IL-17A responsible for lethal side effects of gastric cancer
(Kanazawa University) The formation of scar tissue, or fibrosis, as gastric cancer disseminates throughout the peritoneum can be more lethal than the cancer itself and can interfere with chemotherapy. Researchers from Kanazawa University have now found that proinflammatory cytokine IL-17A from mast cells heavily influences the degree of fibrosis and causes structural changes in peritoneal cells. Preventing mast cells from releasing IL-17A may therefore be a promising treatment strategy for gastric cancer patients with peritoneal dissemination. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 26, 2020 Category: Cancer & Oncology Source Type: news

Oncotarget: Paradox breaker BRAF inhibitors in BRAF mutant colorectal cancer
(Impact Journals LLC) Oncotarget Volume 11, Issue 34 features Figure 1, " BRAF inhibitor-induced changes in cell viability, " by Pickles, et which reported that the BEACON CRC trial demonstrated a survival advantage over chemotherapy for a combination of targeted agents comprising the potent BRAF inhibitor encorafenib together with cetuximab and binimetinib. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 25, 2020 Category: Cancer & Oncology Source Type: news

Single-cell RNA sequencing sheds new light on cancer cells' varied response to chemotherapy
(Michigan Medicine - University of Michigan) Single-cell analysis, done in three colon cancer cell lines, is believed to be the first to profile transcriptome-level changes in response to DNA damage across individual cells. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 25, 2020 Category: International Medicine & Public Health Source Type: news

Cancer and its treatment may accelerate the aging process in young patients
(Wiley) A new study examines the effects of cancer and its treatment on the aging process. Investigators found that expression of a gene associated with aging is higher in young patients with cancer after treatment with chemotherapy and in young cancer survivors who are frail. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society (ACS). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 24, 2020 Category: Cancer & Oncology Source Type: news

Consumer Health: Coping with mouth sores caused by cancer treatment
Certain cancer treatments can cause mouth sores that can be painful and distressing. They also can make it difficult for your mouth to heal itself and fend off germs, leading to infections. Chemotherapy and radiation -- alone or combined -- can cause mouth sores. That's because these cancer treatments are intended to kill rapidly growing [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - August 24, 2020 Category: Databases & Libraries Source Type: news

Sofosbuvir/daclatasvir drugs may be effective coronavirus treatment
(Oxford University Press USA) Several new papers in Journal of Antimicrobial Chemotherapy, published by Oxford University Press, suggest successful treatments for COVID-19. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - August 23, 2020 Category: Infectious Diseases Source Type: news

Autologous HER2 CAR T Cells Induce Rhabdomyosarcoma Remission Autologous HER2 CAR T Cells Induce Rhabdomyosarcoma Remission
Infusion of autologous HER2 CAR T cells after lymphodepleting chemotherapy induced remission in a child with metastatic rhabdomyosarcoma (RMS), researchers report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 20, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

New Lung Cancer Trial Could Benefit Mesothelioma Patients
Pharmaceutical giant Merck has teamed up with Novocure to test its cornerstone immunotherapy, pembrolizumab (Keytruda), alongside Tumor Treating Fields. The new phase II clinical research trial is focusing on non-small cell lung cancer and will enroll approximately 66 patients across the U.S. Keytruda, Merck’s anti-PD-1 therapy, works as a checkpoint inhibitor and allows the immune system to identify and attack cancer cells hiding within the PD-1 pathway. The FDA approved Keytruda for mesothelioma as the first immunotherapy treatment for the disease in 2020. Novocure, a global oncology company, has been developing...
Source: Asbestos and Mesothelioma News - August 19, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Researchers discover how enzyme protects cells from DNA damage
(The Mount Sinai Hospital / Mount Sinai School of Medicine) A research team from Mount Sinai has unraveled for the first time the three-dimensional structure and mechanism of a complex enzyme that protects cells from constant DNA damage, opening the door to discovery of new therapeutics for the treatment of chemotherapy-resistant cancers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 17, 2020 Category: Cancer & Oncology Source Type: news

Chemo doorstep drops help to keep cancer patients safe
Thousands of patients with cancer have had chemotherapy delivered to their doors so that they can more safely receive treatment during the coronavirus pandemic. (Source: NHS Networks)
Source: NHS Networks - August 17, 2020 Category: UK Health Source Type: news

Breast cancer patients face 'cruel' postcode lottery for fertility treatment
Chemotherapy given to young women with breast cancer can leave them infertile, meaning many choose to freeze an embryo or their eggs for future IVF (file photo). (Source: the Mail online | Health)
Source: the Mail online | Health - August 15, 2020 Category: Consumer Health News Source Type: news

Drug Combo Prolongs Survival in Acute Myeloid Leukemia
Findings seen for azacitidine + venetoclax in older patients ineligible for intensive chemotherapy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - August 13, 2020 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Conference News, Source Type: news

Understanding 'Chemo Brain' in Children: Researchers Secure $4.6 Million NIH Grant to Identify Those at Risk
August 11, 2020—(BRONX, NY)—Chemotherapy usually cures children diagnosed with acute lymphoblastic leukemia (ALL), but the treatment may hamper brain development and impact key cognitive functions including sensory processing, memory, and attention. Researchers atAlbert Einstein College of Medicine,Children’s Hospital at Montefiore (CHAM), andRutgers Cancer Institute of New Jersey have received a five-year, $4.6 million grant from the National Institutes of Health (NIH) to determine how chemotherapy exerts its damaging effects on the brain. Their long-term objective is to use this information to develop p...
Source: Einstein News - August 11, 2020 Category: Universities & Medical Training Source Type: news

Immunotherapy Combination Extends Mesothelioma Survival
Standard-of-care treatment for unresectable pleural mesothelioma cancer could be changing soon, sparked by a recently completed international study of a novel immunotherapy combination. Patients in the randomized mesothelioma clinical trial who were treated with ipilimumab (Yervoy) and nivolumab (Opdivo) had a median overall survival of 18.1 months, compared to 14.1 months for those receiving chemotherapy. The results of the mesothelioma trial, which was sponsored by Bristol Myers Squibb, were presented at the recent World Conference on Lung Cancer virtual meeting. Authors of the study said it was the first time an immuno...
Source: Asbestos and Mesothelioma News - August 11, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Chemo-Free Management of Mesothelioma on Horizon Chemo-Free Management of Mesothelioma on Horizon
Combination immunotherapy with nivolumab and ipilimumab could replace chemotherapy for patients with treatment-naive mesothelioma, suggest new phase 3 trial data.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 11, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

First US clinical trial testing efficacy of delivering aerosolized chemotherapy
(City of Hope) City of Hope surgical researchers are the first in the nation to open a clinical trial that could one day become an effective way to deliver chemotherapy to abdominal cancer patients who currently have very few treatment options. Ovarian, uterine, gastric and colorectal cancers can be difficult to treat using traditional intravenous chemotherapy, especially when the tumors spread to a thin layer of tissue that lines the abdomen called the peritoneum. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 11, 2020 Category: Cancer & Oncology Source Type: news

The structural basis of Focal Adhesion Kinase activation on lipid membranes unravelled
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) * Patients with glioma - a very common type of tumour originating in the brain - see improvement in survival rates with combined treatment of radiotherapy plus temozolomide* Researchers found a novel mechanism on how tumours evade chemotherapy through genomic rearrangements of the MGMT DNA repair gene* This finding is potentially relevant for updating the methods used to monitor temozolomide efficacy. Genomic rearrangement could be a marker to be detected in blood samples and help make therapeutic decisions (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 11, 2020 Category: Cancer & Oncology Source Type: news

Sintilimab Scintillates in First-line Non-squamous NSCLC Sintilimab Scintillates in First-line Non-squamous NSCLC
The investigational immunotherapy shows progression-free survival rates comparable to pembrolizumab when added to standard chemotherapy in non-squamous NSCLC, but mature survival data are awaited.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 11, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news